HIV/AIDS is a main cause of mortality and morbidity international. In spite of successful interventions and treatment protocols, an HIV vaccine would be the closing prevention and control approach. Ever considering identity of HIV/AIDS, there have been meticulous efforts for vaccine improvement. The specific intention of this paper is to review current vaccine efficacy trials and related improvements and discuss the cutting-edge demanding situations and future directions. Recombinant DNA technology greatly facilitated development of many viral merchandise which were later included into vectors for effective vaccines. Over the years, some of clinical processes have won recognition and encompass the induction of neutralizing antibodies in overdue Eighties, induction of CD8 T cell in early 1990s, and mixture processes currently. Scientists have hypothesized that stimulation of proper sequences of somatic hypermutations could set off broadly reactive neutralizing antibodies (bnAbs) able to effective neutralization and viral elimination. Studies have shown that a number of host and viral elements have an effect on these approaches. Similarly, eliciting precise CD8 T cells immune responses via DNA vaccines maintain destiny promises. In precis, future studies must attention at the continuous combat between host immune responses and ever-evasive viral factors for effective vaccines.